

CITATION REPORT

List of articles citing

Rechallenge prior sildenafil nonresponders

DOI: 10.1038/sj.ijir.3901143

International Journal of Impotence Research, 2004, 16, 64-8.

Source: <https://exaly.com/paper-pdf/36814518/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
31	Current World Literature. <i>Current Opinion in Urology</i> , 2004 , 14, 395-407	2.8	
30	The Sexual Health Inventory for Men (SHIM): a 5-year review of research and clinical experience. <i>International Journal of Impotence Research</i> , 2005 , 17, 307-19	2.3	266
29	Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2005 , 2, 848-55	1.1	30
28	Non-responders to phosphodiesterase type 5 inhibitors: is there a second chance?. <i>The Journal of Men's Health & Gender: the Official Journal of the International Society for Men's Health & Gender</i> , 2006 , 3, 342-349		5
27	Vardenafil rescue rates of sildenafil nonresponders: objective assessment of 327 patients with erectile dysfunction. <i>Urology</i> , 2006 , 68, 397-401	1.6	12
26	A prospective study of the beneficial effects of dose optimization and customized instructions on patient satisfaction with sildenafil citrate (Viagra) for erectile dysfunction. <i>Urology</i> , 2006 , 68, 38-46	1.6	17
25	Sildenafil citrate (Viagra) treatment for erectile dysfunction: An updated profile of response and effectiveness. <i>International Journal of Impotence Research</i> , 2006 , 18, 423-31	2.3	26
24	Salvaging the oral treatment failure patient. <i>Current Sexual Health Reports</i> , 2006 , 3, 20-24	1.2	1
23	Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil? Hypothesis and pilot trial results. <i>Journal of Sexual Medicine</i> , 2006 , 3, 303-8	1.1	64
22	Efficacy of tadalafil in men with erectile dysfunction naïve to phosphodiesterase 5 inhibitor therapy compared with prior responders to sildenafil citrate. <i>Journal of Sexual Medicine</i> , 2006 , 3, 668-675	1.1	14
21	Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction. <i>European Urology</i> , 2006 , 49, 30-7	10.2	43
20	Positive effect of counseling and dose adjustment in patients with erectile dysfunction who failed treatment with sildenafil. <i>European Urology</i> , 2006 , 50, 134-40	10.2	54
19	Phosphodiesterase type 5 inhibitors: the day after. <i>European Urology</i> , 2007 , 51, 75-88; discussion 89	10.2	73
18	A rational combination pharmacotherapy in men with erectile dysfunction who initially failed to oral sildenafil citrate alone: a pilot study. <i>Journal of Sexual Medicine</i> , 2007 , 4, 1136-41	1.1	13
17	Can an educational program optimize PDE5i therapy? A study of Canadian primary care practices. <i>Journal of Sexual Medicine</i> , 2007 , 4, 1404-13	1.1	13
16	JSSM Guidelines for erectile dysfunction. <i>International Journal of Urology</i> , 2008 , 15, 564-76	2.3	8
15	Erectile dysfunction, testosterone deficiency, metabolic syndrome and prostatic disease in Taiwan. <i>Journal of Men's Health</i> , 2008 , 5, 289-296	1.2	2

14	Randomized, double-blind, crossover trial of sildenafil in men with mild to moderate erectile dysfunction: efficacy at 8 and 12 hours postdose. <i>Urology</i> , 2008 , 71, 686-92	1.6	17
13	Options thérapeutiques. 2008 , 484-633		
12	Phosphodiesterase type 5 inhibitors for the management of erectile dysfunction: preference and adherence to treatment. <i>Current Pharmaceutical Design</i> , 2009 , 15, 3486-95	3.3	16
11	Phosphodiesterase type 5 inhibitors: unmet needs. <i>Current Pharmaceutical Design</i> , 2009 , 15, 3476-85	3.3	25
10	Hardness, function, emotional well-being, satisfaction and the overall sexual experience in men using 100-mg fixed-dose or flexible-dose sildenafil citrate. <i>International Journal of Impotence Research</i> , 2010 , 22, 284-9	2.3	9
9	Atorvastatin improves the response to sildenafil in hypercholesterolemic men with erectile dysfunction not initially responsive to sildenafil. <i>International Journal of Impotence Research</i> , 2010 , 22, 51-60	2.3	48
8	SOP conservative (medical and mechanical) treatment of erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2013 , 10, 130-71	1.1	117
7	Improvement in erection hardness and intercourse success with first dose of sildenafil citrate 100 mg. <i>International Journal of General Medicine</i> , 2013 , 6, 849-54	2.3	5
6	Nonresponse to phosphodiesterase 5 inhibitors in erectile dysfunction. Part 1. <i>Human Andrology</i> , 2014 , 4, 23-29	1	0
5	Canadian consensus algorithm for erectile rehabilitation following prostate cancer treatment. <i>Canadian Urological Association Journal</i> , 2018 , 239-245	1.2	3
4	Erectile Dysfunction. <i>Primary Care - Clinics in Office Practice</i> , 2019 , 46, 249-255	2.2	46
3	Practical Approaches to Treat ED in PDE5i Nonresponders. 2020 , 11, 1202-1218		3
2	Behavioural Therapy and Counselling. 2006 , 598-607		9
1	Evaluation and Management of Erectile Dysfunction. 2021 , 93-126		